FBMD Basis for investigation, strategy, & intervention

The endocannabinoid system modulates essential cell signaling targets for energy homeostasis. PhytoCannas supplement, bind, and activate transmembrane G-protein-coupled receptors in the central nervous system and periphery. Modulation of CB1 and CB2 receptor activity reveals potential therapeutic targets to reduce health and mental health issues and invigorate a spectrum of coping mechanisms. Rational oleoresin selection and dosing result in valuable clinically relevant intentional evidence-based outcomes and healthy wellbeing.

• Cannabinoids — A class of fatty acids including 419 natural PhytoCannas from Cannabis sativa, and 6 EndoCannas produced on-demand by mammalians, binding with, interacting, and modulating through the ECS Receptor system. 

• EndoCannabinoid System, ECS — A widespread transmembrane neuro- and immune-modulating animal supersystem enabling and regulating crucial health and mental health response. Class1 Receptors in the central nervous system (CNS) manage the development, synaptic plasticity, and response to endogenous and environmental insults—CB1. Class 2 immune system receptors with transient receptor potential (TRP) channels and peroxisome proliferation-activated receptors (PPARs) handle regulating energy metabolism—CB2.

• ECS Receptors -- Effects of Phyto- and Endo-cannabinoids are mediated by CB1 and CB2 configured cannabinoid receptors, with other PPAR and TRP receptor channels. CB1 receptors are abundant in the central nervous system (CNS), particularly in the cortex, basal ganglia, hippocampus, and cerebellum. CB2 receptors are expressed at lower levels in the CNS, primarily present in microglia and vascular elements. Highly inducible, CB2 increases up to 100 fold following tissue injury or during inflammation.

• EndoCannas — Six (6) endogenous cannabinoids are lipids that engage cannabinoid receptors, affecting behavior in a fashion recapitulating the effects produced by the psychoactive components of cannabis. Upon demand—by activation of G-protein-coupled receptors or by depolarization--EndoCannas are liberated in one or two rapid enzymatic steps and released into the extracellular space.

• PhytoCannas -- 419 structurally diverse natural molecular constituents found on the surface of Cannabaceae. Derivatives from a common C18-25 precursor, cannabigerolic acid, CBGA. The PhytoCanna precursors are formed through the reaction between geranyl pyrophosphate with olivetolic and divarinic acids. PhytoCannas simulate the final EndoCanna geometries and modulate the EndoCannabinoid System Receptors.

• MX:Profile OleoResins -- Nutraceutically curated PhytoCanna OleoResins demonstrate consistency and clinically relevant potential because they supplement and support the ECS. MX:Profiles are capable of intentional medicinal outcomes across mammalian populations and may benefit from health and mental health outcomes the pharmacodynamic effect of the profile (pD) at specifically delivered pharmacokinetic (pK) concentrations deliver.

• MX:Scale Project — A classification structure for a pharmacologic model linking health sciences expectations, chemical composition, and resultant binding affinities, with rational wellness outcomes within clinical populations. The MX:Scale project clarifies, classifies, and communicates the intended effects of cannabis as a nutraceutical capable of evidence-based outcomes. It bridges the final capability of a cannabis OleoResin with expectation and demand for the patient. The project incorporates the actual pK/pD metrics while evaluating pharmacoConsistancy (pC, p(V)) robustness across populations and comorbidities. The MX:Scale tracks the pharmacological trends across dosing regimens that influence receptor binding affinities and pharmacodynamics. The project reports MX:Supply of Effect potentials and MX:Demand for Effects, creating a real-time MX:Forecast of availability and unmet need.

• FurBabyMD:OCO — Observational Clinic and Outcome programs explore putative solutions and their effective outcomes based on the MX:Scale Project data, dosing impact, and root causation models for patients exploring cannabis as a rational therapeutic agent. the FBMD:OCO leverages epidemiologic and health services records to identify evidence-based strategies and valuable outcomes. Comparative assessment, progress, and evaluation are performed by independent health inventories, professionals, screens, and assay.

• Weed Propaganda -- Hype and spurious claims for weed that promote fictitious miracles and cures. Big Weed propaganda doesn’t result in consistent, utilitarian, or useful effects or outcomes and includes terms like  %THC, %CBD, THC:CBD ratio, Color, Strain name, Terpene names, Hybrid, %Sativa, %Indica, Entourage, etc. Although popular propaganda, they do not identify the function, efficacious details, nor quality, yet always associated with increased pricing, because they intentionally and effectively confuse and trick buyers.

>> Request more information  <<